Chiasma Inc (NASDAQ:CHMA) was up 7.6% on Tuesday . The company traded as high as $5.56 and last traded at $5.49, approximately 262,800 shares changed hands during trading. A decline of 28% from the average daily volume of 367,063 shares. The stock had previously closed at $5.10.
A number of analysts have weighed in on CHMA shares. Piper Jaffray Companies started coverage on shares of Chiasma in a research note on Wednesday, July 31st. They set an “overweight” rating and a $11.00 target price on the stock. Cantor Fitzgerald set a $18.00 target price on shares of Chiasma and gave the stock a “buy” rating in a research note on Friday, September 13th. Zacks Investment Research cut shares of Chiasma from a “buy” rating to a “hold” rating in a research note on Monday, October 14th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Chiasma in a research note on Thursday, November 7th. Finally, Brookline Capital Management reaffirmed a “buy” rating on shares of Chiasma in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $12.30.
The company has a market cap of $210.92 million, a P/E ratio of -4.29 and a beta of 1.19. The firm’s 50 day moving average is $5.10 and its two-hundred day moving average is $5.91.
In related news, Director Roni Mamluk sold 50,000 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $5.59, for a total value of $279,500.00. Following the transaction, the director now owns 50,000 shares in the company, valued at $279,500. The transaction was disclosed in a document filed with the SEC, which is available through this link. 8.30% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its holdings in Chiasma by 11.4% in the third quarter. Rhumbline Advisers now owns 22,218 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 2,265 shares during the period. Cubist Systematic Strategies LLC raised its holdings in shares of Chiasma by 35.4% during the second quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 3,722 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Chiasma during the third quarter valued at about $53,000. Tower Research Capital LLC TRC raised its holdings in shares of Chiasma by 461.4% during the third quarter. Tower Research Capital LLC TRC now owns 14,938 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 12,277 shares during the period. Finally, Quantitative Systematic Strategies LLC acquired a new position in shares of Chiasma during the second quarter valued at about $100,000. Institutional investors and hedge funds own 53.90% of the company’s stock.
Chiasma Company Profile (NASDAQ:CHMA)
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Featured Story: Why do companies issue monthly dividends?
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.